[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594670":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":45,"responsibleParty":64,"collaborators":26,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":26,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":26,"enrollmentInfo":75,"targetDuration":26,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":47,"whyStopped":26,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Stanford University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"3-Fraction Brachytherapy Arm","EXPERIMENTAL","Patients who meet dosimetric criteria at the first brachytherapy session (HR CTV D90 \\> 85 Gy and acceptable OAR constraints) will receive an investigational 3-fraction HDR brachytherapy regimen (24 Gy total).",[13],"Radiation: 3-Fraction HDR Brachytherapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Investigational Treatment","ACTIVE_COMPARATOR","Patients who do not meet dosimetric criteria for the investigational regimen will receive the institutional standard-of-care regimen of 4 fractions (28 Gy total).",[19],"Radiation: 4-Fraction HDR Brachytherapy",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"RADIATION","3-Fraction HDR Brachytherapy","8 Gy per fraction for 3 fractions (total 24 Gy) for patients with locally advanced cervical cancer, based on individualized planning.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"4-Fraction HDR Brachytherapy","7 Gy per fraction for 4 fractions (total 28 Gy) as the standard-of-care brachytherapy regimen.",[15],[32],{"name":33,"affiliation":5,"role":34},"Elizabeth Kidd, MD","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Alyssa Yauger","CONTACT","(650) 498-5271","ayauger@stanford.edu",{"name":42,"role":38,"phone":43,"phoneExt":26,"email":44},"Jillian Skerchak","(650) 721-4072","jskerch1@stanford.edu",[46],{"facility":5,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"RECRUITING","Palo Alto","California","94304","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-122.14302,37.44188,{"lat":57,"lon":56},[60,62,63],{"name":37,"role":38,"phone":61,"phoneExt":26,"email":40},"650-498-5271",{"name":42,"role":38,"phone":43,"phoneExt":26,"email":44},{"name":33,"role":34,"phone":26,"phoneExt":26,"email":26},{"type":65,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100594670","phase-2-phase-ii-trial-comparison-of-3-vs-4-fractions-brachy-fit-100594670",false,"NCT07022470","Phase II Trial Comparison of 3 vs 4 Fractions (BRACHY-FIT).","Brachytherapy Fractionation Individualized by Treatment Feasibility in Cervical Cancer: Phase II Trial Comparison of 3 vs 4 Fractions (BRACHY-FIT).","Inclusion Criteria:\n\n* Histologically documented malignancy of the cervix and planned to receive brachytherapy as part of definitive treatment.\n* ECOG performance status of 0-2\n* Age ≥ 18 years old.\n* Ability to understand and the willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Contraindication to receiving radiotherapy as determined by treating radiation oncologist.\n* Contraindication to receiving MRI.\n* Prior radiation to the pelvis \\> 3 months ago\n* Age \\\u003C 18 years old.\n* Pregnant or breast-feeding","ALL","18 Years",{"count":76,"type":77},41,"ESTIMATED","INTERVENTIONAL",[80],"PHASE2","This is a prospective non-randomized clinical trial to evaluate the feasibility of 3 fraction versus a standard 4 fraction high dose rate brachytherapy regimen in patients with locally advanced cervical cancer.",[83],"Cervical Cancers",[85],"high dose rate brachytherapy","2026-06-10",{"date":88,"type":89},"2026-06-12","ACTUAL",{"date":91,"type":89},"2025-06-03",{"date":93,"type":77},"2028-06",{"name":5,"class":6},1]